By Fineline Cube Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that it has submitted a marketing application to China’s National Medical Products Administration (NMPA) for a new indication of its proprietary drug Crisugabalin capsules, intended for the treatment of neuropathic pain in adults.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Application Type | New indication marketing authorization |
| Product | Crisugabalin capsules (third-generation voltage-gated calcium channel modulator) |
| Proposed Indication | Treatment of neuropathic pain in adults |
| Submission Date | 14 Jul 2026 |
| Existing Approvals | Adult diabetic peripheral neuropathic pain and postherpetic neuralgia |
Drug Profile & Mechanism of Action
- Molecule: Third-generation voltage-gated calcium channel modulator
- Intellectual Property: Proprietary compound independently developed by Haisco with full IP rights
- Mechanism: Binds with high affinity to the α₂δ subunit of presynaptic neuronal membranes
- Pharmacological Effects: Inhibits calcium influx and reduces release of excitatory neurotransmitters (glutamate, norepinephrine, substance P)
- Therapeutic Activities: Anti-epileptic, analgesic, and anti-anxiety properties through alleviation of central sensitization
Clinical Development Status
| Parameter | Status |
|---|---|
| Drug Class | Proprietary third-generation calcium channel modulator |
| Previous Approvals | Diabetic peripheral neuropathic pain, postherpetic neuralgia |
| New Indication | Broad neuropathic pain in adults |
| Development Stage | Marketing application submitted |
| Expected Review Timeline | Standard NMPA review period of 180-270 days |
Neuropathic pain affects an estimated 7-10% of the global population and represents a significant therapeutic challenge due to limited treatment options and variable patient response to existing medications. Haisco’s expansion of Crisugabalin’s indication could address this substantial unmet medical need.
Market Impact & Outlook
- Market Opportunity: The global neuropathic pain market is projected to reach $9.5 billion by 2028, with China representing one of the fastest-growing segments due to aging demographics and increasing diabetes prevalence.
- Competitive Advantage: As a third-generation calcium channel modulator with established safety data from previous approvals, Crisugabalin may offer improved efficacy and tolerability compared to first and second-generation agents.
- Revenue Potential: Analysts estimate peak annual sales of ¥800 million-¥1.2 billion ($110-165 million) if the new indication is approved, representing a 30-40% expansion of the drug’s current market potential.
- Strategic Significance: This application demonstrates Haisco’s commitment to maximizing the value of its proprietary compounds through indication expansion, a strategy that has proven successful for other Chinese pharmaceutical innovators.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory approvals, market opportunities, and revenue projections for Crisugabalin. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market adoption rates.-Fineline Info & Tech